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Low aspirin use and high prevalence of pre-
eclampsia risk factors among pregnant women 
in a multinational SLE inception cohort
Women with systemic lupus erythematosus (SLE) carry a substan-
tially higher risk for pre-eclampsia compared with the general 
population.1 Aspirin reduces the risk of pre-eclampsia in high-
risk pregnancies by more than half2 and thus is recommended in 
SLE.3–5 The European League Against Rheumatism recommends 
aspirin in SLE pregnancies, particularly in those with nephritis 
or positive antiphospholipid antibodies (aPL).5 Despite this, 
little is known about current practice. Therefore, we assessed the 
prevalence of aspirin use in SLE pregnancies within the Systemic 
Lupus International Collaborating Clinics inception cohort, 
which has been described elsewhere.6
SLE women aged 18–45 with a pregnancy documented at 
one or more annual study visits (spanning 2000–2017) were 
included. For each pregnant visit, aspirin use, traditional 
pre-eclampsia risk factors (hypertension, chronic kidney 
disease, diabetes, nulliparity, body mass index ≥35, age >40), 
aPL and active lupus nephritis were assessed (see variable defi-
nitions in online supplementary material). Aspirin use was 
compared among those with and without each/any risk factor, 
and over time.
We identified 475 pregnancies among 300 women. Mean 
SLE duration at the time of pregnancy was 5.6 years (SD 3.1). 
Half (51%) of pregnancies had ≥1 traditional pre-eclampsia 
risk factor, 34/104 (33%) had positive aPL and 53/475 (11%) 
had nephritis (table 1). Aspirin was used in 121 (25%) preg-
nancies. While a third of pregnancies in Caucasians (71/209, 
34%, 95% CI 28% to 41%) and Hispanics (20/62, 32%, 95% 
CI 22% to 45%) were aspirin exposed, only 9/88 (10%, 95% 
CI 5% to 18%) and 7/66 (11%, 95% CI 5% to 20%) of preg-
nancies in Black and Asian subjects were respectively aspirin 
exposed. Aspirin use did not differ among pregnancies with or 
without ≥1 traditional risk factor (58/234, 25% (95% CI 20% 
to 31%) vs 63/241, 26% (95% CI 21% to 32%)), any tradi-
tional risk factor individually, or nephritis (see online supple-
mentary table 1). There was a potential trend for increased 
aspirin use among pregnancies with positive aPL (13/34, 38%, 
95% CI 24% to 55%) compared with those without aPL 
(16/70, 23%, 95% CI 15% to 34%), although CI overlapped. 
Sensitivity analyses excluding multiple pregnancies within 
the same women yielded similar results. Aspirin use did not 
increase from 2000 to 2017 (χ2 test for trend in proportions, 
p=0.13).
Our study is the first to assess aspirin use in SLE pregnancies 
according to the presence of pre-eclampsia risk factors. Among 
the 475 SLE pregnancies in this prospective, multinational 
inception cohort, additional pre-eclampsia risk factors were 
present in half, while aspirin was taken in only one-quarter 
and did not differ from background aspirin use among the 
same women at non-pregnant visits (see online supplemen-
tary material). Even without considering SLE itself as a major 
risk factor, aspirin use was no more prevalent among those 
with other traditional indications for aspirin in pregnancy, and 
the majority of those with aPL and nephritis were not taking 
aspirin. The low aspirin use among Black SLE subjects is note-
worthy given the worse reproductive outcomes observed in 
this population.7
Study limitations include lack of data on gestational age 
and pregnancy outcomes. In addition, aspirin could have been 
introduced at/or following the study visit when the pregnancy 
was documented, highlighting the importance of the rheuma-
tologist in reviewing aspirin use and initiating it, if not already 
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Table 1 Characteristics of SLE pregnancies overall and according to 
aspirin use
Characteristic
All pregnant 
visits 
(n=475)*
Pregnant 
visits with 
aspirin 
(n=121)
Pregnant visits 
without aspirin 
(n=354)
Patient characteristic
Age, mean (SD) 31.0 (4.9) 30.5 (4.6) 31.2 (5.0)
Ethnicity, n (%) 
  Asian 66 (14) 7/66 (11) 59/66 (89)
  Native North American 3 (1) 2/3 (67) 1/3 (33)
  Black 88 (19) 9/88 (10) 79/88 (90)
  Caucasian 209 (44) 71/209 (34) 138/209 (66)
  Hispanic 62 (13) 20/62 (32) 42/62 (68)
  Indian subcontinent 25 (5) 8/25 (32) 17/25 (68)
  Other 22 (5) 4/22 (18) 18/22 (82)
Country, n (%) 
  Canada 121 (25) 27/121 (22) 94/121 (78)
  USA 105 (22) 20/105 (19) 85/105 (81)
  Mexico 52 (11) 19/52 (37) 33/52 (63)
  Europe 146 (31) 49/146 (34) 97/146 (66)
  South Korea 51 (11) 6/51 (12) 45/51 (88)
Any postsecondary education, n (%) 310/452 (69) 69/310 (22) 241/310 (78)
BMI, mean (SD) 25.8 (5.9) 26.3 (5.2) 25.6 (6.1)
Obstetrical history
  Parity, mean (SD) 1.1 (1.0) 1.1 (1.0) 1.2 (1.0)
  Nulliparous, n (%) 134/461 (29) 37/134 (28) 97/134 (72)
  Previous fetal loss <24 weeks, 
n (%)
84/456 (18) 22/84 (26) 62/84 (74)
SLE characteristics
  Disease duration (years), mean (SD) 5.6 (3.3) 5.6 (3.3) 5.6 (3.3)
  SLEDAI, mean (SD) 3.3 (3.8) 3.0 (3.6) 3.4 (3.9)
  SLICC damage score, mean (SD) 0.5 (1.0) 0.6 (1.0) 0.5 (1.0)
  Any positive aPL, n (%) 34/104 (33) 13/34 (38) 21/34 (62)
  LAC, n (%) 19/104 (18) 6/19 (32) 13/19 (68)
  ACL, n (%) 12/104 (12) 3/12 (25) 9/12 (75)
  GP1 IgG, n (%) 18/104 (17) 9/18 (50) 9/18 (50)
  Nephritis, n (%) 53(11) 11/53(21) 42/53 (79)
Comorbidities
  Any renal disease†, n (%) 83 (17) 17/83 (20) 66/83 (80)
  CKD (eGFR≤90 mL/min/1.73 m²), 
n (%)
43/459 (9) 6/43 (14) 37/43 (86)
  CKD stage ≤3 (eGFR≤60 mL/
min/1.73 m²), n (%)
11/459 (2) 5/11 (45) 6/11 (55)
  Hypertension, n (%) 79 (17) 24/79 (30) 55/79 (70)
  Taking anticoagulation, n (%) 28 (6) 12/28 (43) 15/28 (54)
Year of pregnancy visit
  2000– 2004, n (%) 39 (8) 11/39 (28) 28 (72)
  2005– 2009, n (%) 157 (33) 46/157 (29) 111/157 (71)
  2010– 2014, n (%) 218 (46) 52/218 (24) 166/218 (76)
  2015– 2017, n (%) 61 (13) 12/61 (20) 49/61 (80)
*Denominator=475 unless otherwise stated.
†Includes chronic kidney disease, active nephritis and/or nephrotic syndrome within the last 
year.
ACL, anticardiolipin antibody; aPL, antiphospholipid antibody; BMI, body mass index; 
CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; GP1, anti-B2-
glycoprotein-1; LAC, lupus anticoagulant; SLE, systemic lupus erythematosus; SLEDAI, 
Systemic Lupus Erythematosus Disease Activity Index; SLICC, Systemic Lupus International 
Collaborating Clinics.
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done, in pregnant SLE women. However, assuming either a 
somewhat normal or a left-skewed distribution of gestational 
ages at the pregnant visits, a substantial proportion of visits 
would have taken place after 12–16 weeks’ gestation, by which 
time aspirin should have been initiated.2 3
In conclusion, we have potentially identified an important 
gap between practices and current recommendations for the 
care of pregnant SLE women, and call for further studies of 
factors contributing to aspirin use in lupus pregnancies.
Arielle Mendel,1 Sasha B Bernatsky,1,2 John G Hanly,3 Murray B Urowitz,4 
Ann Elaine Clarke,5 Juanita Romero-Diaz,6 Caroline Gordon,7,8 
Sang-Cheol Bae,9 Daniel J Wallace,10 Joan T Merrill,11 Jill P Buyon,12 
David A Isenberg,13 Anisur Rahman,13 Ellen M Ginzler,14 Michelle Petri,15 
Mary Anne Dooley,16 Paul R Fortin,17 Dafna D Gladman,4 
Kristján Steinsson,18 Rosalind Ramsey-Goldman,19 
Munther A Khamashta,20 Cynthia Aranow,21 Meggan Mackay,21 
Graciela S Alarcón,22 Susan Manzi,23 Ola Nived,24 Andreas Jönsen,24 
Asad A Zoma,25 Ronald F van Vollenhoven,26 Manuel Ramos-Casals,27 
Guillermo Ruiz-Irastorza,28 Sam Lim,29 Ken C Kalunian,30 Murat Inanc,31 
Diane L Kamen,32 Christine A Peschken,33 Søren Jacobsen,34 
Anca Askanase,35 Jorge Sanchez-Guerrero,36 Ian N Bruce,37,38 
Nathalie Costedoat-Chalumeau,39 Évelyne Vinet1,2
1Division of Rheumatology, McGill University Health Centre, Montreal, Quebec, 
Canada
2Division of Clinical Epidemiology, Research Institute of the McGill University Health 
Center, Montreal, Quebec, Canada
3Division of Rheumatology, Department of Medicine and Department of Pathology, 
Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, Nova 
Scotia, Canada
4Lupus Program, Centre for Prognosis Studies in the Rheumatic Disease and Krembil 
Research Institute, Toronto Western Hospital, University of Toronto, Toronto, Ontario, 
Canada
5Division of Rheumatology, Cumming School of Medicine, University of Calgary, 
Calgary, Alberta, Canada
6Department of Immunology and Rheumatology, Instituto Nacional de Ciencias 
Médicas y Nutrición, Tlalpan, Mexico
7Rheumatology Research Group, Institute of Inflammation and Ageing, University of 
Birmingham, Birmingham, UK
8Rheumatology Department, City Hospital, Sandwell and West Birmingham Hospitals 
NHS Trust, Birmingham, UK
9Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, 
Seoul, Republic of Korea
10Cedars-Sinai Medical Centre, David Geffen School of Medicine at UCLA, Los 
Angeles, California, USA
11Department of Clinical Pharmacology, Oklahoma Medical Research Foundation, 
Oklahoma City, Oklahoma, USA
12Division of Rheumatology, Department of Medicine, New York School of Medicine, 
New York City, New York, USA
13Department of Medicine, Centre for Rheumatology, University College London, 
London, UK
14Department of Medicine, SUNY Downstate Medical Center, Brooklyn, New York, 
USA
15Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, 
Maryland, USA
16Thurston Arthritis Research Center, University of North Carolina, Chapel Hill, North 
Carolina, USA
17Division of Rheumatology, Centre Hospitalier Universitaire de Québec et Université 
Laval, Québec City, Quebec, Canada
18Center for Rheumatology Research, Landspitali University Hospital, Reykjavik, 
Iceland
19Division of Rheumatology, Feinberg School of Medicine, Northwestern University 
Chicago, Chicago, Illinois, USA
20Lupus Research Unit, The Rayne Institute, St Thomas’ Hospital, King’s College 
London School of Medicine, London, UK
21Lupus Center of Excellence, Feinstein Institute for Medical Research, Manhasset, 
New York, USA
22Department of Medicine, University of Alabama at Birmingham, Birmingham, 
Alabama, USA
23Lupus Center of Excellence, Allegheny Health Network, Pittsburgh, Pennsylvania, 
USA
24Department of Clinical Sciences and Rheumatology, Lund University, Lund, Sweden
25Lanarkshire Centre for Rheumatology, Hairmyres Hospital, East Kilbride, UK
26Unit for Clinical Therapy Research (CliTRID), Karolinska Institute, Stockholm, 
Sweden
27Josep Font Autoimmune Diseases Laboratory, IDIBAPS, Department of Autoimmune 
Diseases, Hospital Clínic, Barcelona, Spain
28Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces 
Health Research Institute, Hospital Universitario Cruces, University of the Basque 
Country, Barakaldo, Spain
29Division of Rheumatology, Emory University School of Medicine, Atlanta, Georgia, 
USA
30University of California San Diego School of Medicine, La Jolla, California, USA
31Division of Rheumatology, Department of Internal Medicine, Istanbul Medical 
Faculty, Istanbul University, Istanbul, Turkey
32Department of Medicine, Medical University of South Carolina, Charleston, South 
Carolina, USA
33Department of Medicine, University of Manitoba, Winnipeg, Manitoba, Canada
34Copenhagen Lupus and Vasculitis Clinic, Section 4242, Center for Rheumatology 
and Spine Diseases, Rigshospitalet, University of Copenhagen, Copenhagen, 
Denmark
35Hospital for Joint Diseases, Seligman Centre for Advanced Therapeutics, New York 
University, New York City, New York, USA
36Department of Rheumatology, Mount Sinai Hospital and University Health 
Network, University of Toronto, Toronto, Ontario, Canada
37NIHR Manchester Biomedical Research Centre, Central Manchester University 
Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, 
Manchester, UK
38Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal 
Research, Faculty of Biology, Medicine and Health, School of Biological Sciences, The 
University of Manchester, Manchester, UK
39Centre de Reference Maladies Auto-immunes et Systemiques Rares, Service de 
Medecine Interne, Hospital Cochin, Paris, France
Correspondence to Dr Évelyne Vinet, Research Institute of the McGill University 
Health Centre, Montréal, QC H4A 3S5, Canada;  evelyne. vinet@ mcgill. ca
Handling editor Josef S Smolen
Contributors EV had full access to all the data in this study and takes full 
responsibility as a guarantor for the integrity of the data and the accuracy of the 
data analysis. EV, AM, SBB, JGH, MBU, AEC, JRD, CG, SCB, DJW, JTM, JPB, DAI, 
AR, EMG, MP, MAD, PRF, DDG, KS, RRG, MAK, CA, MM, GSA, SM, ON, AJ, AAZ, 
RFV, MRC, GRI, SL, KCK, MI, DLK, CAP, SJ, AA, JSG, INB and NCC conceived and 
designed the study. EV, AM, SBB, JGH, MBU, AEC, JRD, CG, SCB, DJW, JTM, JPB, DAI, 
AR, EMG, MP, MAD, PRF, DDG, KS, RRG, MAK, CA, MM, GSA, SM, ON, AJ, AAZ, RFV, 
MRC, GRI, SL, KCK, MI, DLK, CAP, SJ, AA, JSG, INB and NCC analysed the data. EV, 
AM, SBB, JGH, MBU, AEC, JRD, CG, SCB, DJW, JTM, JPB, DAI, AR, EMG, MP, MAD, 
PRF, DDG, KS, RRG, MAK, CA, MM, GSA, SM, ON, AJ, AAZ, RFV, MRC, GRI, SL, 
KCK, MI, DLK, CAP, SJ, AA, JSG, INB and NCC interpreted the data and drafted the 
manuscript.
Funding This study was funded through a McGill University Health Centre Research 
Award. EV receives a salary support from a Fonds de Recherche Québec Santé 
Clinical Research Scholar-Junior 1 Award. SCB is supported by the Bio & Medical 
Technology Development Program of the National Research Foundation funded by 
the Ministry of Science and ICT (NRF-2017M3A9B4050335). SJ is supported by The 
Danish Rheumatism Association (A-3865). AEC is supported by an Arthritis Society 
Chair in Rheumatic Diseases. The Hopkins Lupus Cohort is supported by a National 
Institutes of Health grant (R01 AR069572) awarded to MP. The Birmingham SLICC 
cohort was funded by a Lupus UK grant awarded to CG.
Competing interests None declared.
Patient consent for publication Not required.
Ethics approval McGill University Health Centre.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement No additional data available.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non-commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non-commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
© Author(s) (or their employer(s)) 2018. Re-use permitted under CC BY-NC. No 
commercial re-use. See rights and permissions. Published by BMJ.
 o
n
 4 January 2019 by guest. Protected by copyright.
http://ard.bmj.com/
Ann R
heum
 D
is: first published as 10.1136/annrheum
dis-2018-214434 on 20 Decem
ber 2018. Downloaded from
 
3Ann Rheum Dis Month 2018 Vol 0 No 0
Letter
 ► Additional material is published online only. To view please visit the journal 
online (http:// dx. doi. org/ 10. 1136/ annrheumdis- 2018- 214434).
To cite Mendel A, Bernatsky SB, Hanly JG, et al. Ann Rheum Dis Epub ahead of 
print: [please include Day Month Year]. doi:10.1136/annrheumdis-2018-214434
Received 12 September 2018
Revised 21 November 2018
Accepted 3 December 2018
Ann Rheum Dis 2018;0:1–3. doi:10.1136/annrheumdis-2018-214434
RefeRences
 1 Clowse MEB, Jamison M, Myers E, et al. A national study of the complications of lupus 
in pregnancy. Am J Obstet Gynecol 2008;199:127.e1–127.e6.
 2 Bujold E, Roberge S, Lacasse Y, et al. Prevention of preeclampsia and intrauterine 
growth restriction with aspirin started in early pregnancy: a meta-analysis. Obstet 
Gynecol 2010;116(2 Pt 1):402–14.
 3 Visintin C, Mugglestone MA, Almerie MQ, et al. Management of hypertensive disorders 
during pregnancy: summary of NICE guidance. BMJ 2010;341:c2207.
 4 LeFevre ML, U.S. Preventive Services Task Force. Low-dose aspirin use for the prevention 
of morbidity and mortality from preeclampsia: U.S. Preventive Services Task Force 
recommendation statement. Ann Intern Med 2014;161:819–26.
 5 Andreoli L, Bertsias GK, Agmon-Levin N, et al. EULAR recommendations for women’s 
health and the management of family planning, assisted reproduction, pregnancy and 
menopause in patients with systemic lupus erythematosus and/or antiphospholipid 
syndrome. Ann Rheum Dis 2017;76:476–85.
 6 Urowitz MB, Gladman D, Ibañez D, et al. Clinical manifestations and coronary artery 
disease risk factors at diagnosis of systemic lupus erythematosus: data from an 
international inception cohort. Lupus 2007;16:731–5.
 7 Buyon JP, Kim MY, Guerra MM. Predictors of Pregnancy Outcome in a Prospective, 
Multiethnic Cohort of Lupus Patients. Ann Intern Med 2015;163:153–63.
 o
n
 4 January 2019 by guest. Protected by copyright.
http://ard.bmj.com/
Ann R
heum
 D
is: first published as 10.1136/annrheum
dis-2018-214434 on 20 Decem
ber 2018. Downloaded from
 
